Farabi Pharmaceutical (XTEH:DFRB1) EPS (Basic): IRR (TTM As of . 20)


What is Farabi Pharmaceutical EPS (Basic)?

Farabi Pharmaceutical XTEH:DFRB1 EPS (Basic) is IRR as of . 20.

Farabi Pharmaceutical's basic earnings per share (Basic EPS) for the three months ended in . 20 was IRR0.00. Farabi Pharmaceutical does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in . 20.

Farabi Pharmaceutical's EPS (Diluted) for the three months ended in . 20 was IRR0.00. Farabi Pharmaceutical does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in . 20.

Farabi Pharmaceutical's EPS without NRI for the three months ended in . 20 was IRR0.00. Farabi Pharmaceutical does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Farabi Pharmaceutical  (XTEH:DFRB1) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Farabi Pharmaceutical EPS (Basic) Related Terms

Farabi Pharmaceutical EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical EPS (Basic) Chart

Farabi Pharmaceutical Annual Data
Trend
EPS (Basic)

Farabi Pharmaceutical Quarterly Data
EPS (Basic)

Farabi Pharmaceutical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Farabi Pharmaceutical's Basic EPS for the fiscal year that ended in . 20 is calculated as

Basic EPS (A: . 20 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-)/0
=

Farabi Pharmaceutical's Basic EPS for the quarter that ended in . 20 is calculated as

Basic EPS (Q: . 20 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-)/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of IRR mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a EPS (Basic) of IRR as of . 20. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's EPS (Basic) too high?
Farabi Pharmaceutical's current EPS (Basic) is IRR.
How does Farabi Pharmaceutical's EPS (Basic) compare to IMNPQ and INNV?
Farabi Pharmaceutical's EPS (Basic) of IRR can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Farabi Pharmaceutical and its competitors. Farabi Pharmaceutical's current EPS (Basic) is IRR. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current EPS (Basic) of IRR. The current EPS (Basic) is IRR. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current EPS (Basic) is IRR as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.